Du är här



CellCura ASA (Oslo Axess: CELL), announces its results for the first quarter,
2014. A presentation will be held at 9 PM today at the Company's office at
Vika Atrium, Munkedamsveien 45 A, 5th floor, Oslo.

Higlights from the quarter and subsequent period:
· CellCura has been working on a revised version of the ERM workstation
(version 1.5) which will feature reduced production costs and new features.
The new features can be retrofitted to the current installation base as part
of a future upgrade package.

· CellCura has been focusing on expanding the existing customers' solutions
with new modules in order to cover more of the processes in the clinics.
· CellCura has fine-tuned the composition of certain PFM products on the back
of advice from the original inventor. This has been completed in order to
further enhance specific value adding properties of certain media types. A
new batch has been produced and tested, with products shipped to complete the
first orders.

· The company is working on growing sales in unregulated markets and have
already signed and expect to sign new distributor agreements in SE Asia. This
will allow the company to further develop its sales and distribution platform
ahead of introducing products to regulated markets once the CE approval is in

Quarterly report attached.

Oslo, 30 May 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
Phone: + 47 911 08 693

Q1 2014


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cellcura ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.